Chemo Regimen for Ovarian Cancer Fayetteville NC

Dose-dense chemotherapy improves survival in women with advanced ovarian cancer, Japanese researchers say. Currently, paclitaxel and carboplatin given every three weeks is considered standard first-line chemotherapy for advanced epithelial ovarian cancer. However, dose-dense weekly treatment with paclitaxel is seen as a way to increase progression-free and overall survival in these patients in Fayetteville, according to the new study findings.

Edmund L Paquette, MD
(910) 907-8393
117 Stedman St
Fayetteville, NC
Specialties
Urology
Gender
Female
Education
Medical School: Brown Univ Program In Med, Providence Ri 02912
Graduation Year: 1994

Data Provided by:
William Stewart Powell, MD
(910) 484-1312
2021 Raeford Rd
Fayetteville, NC
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Ms Sch Of Med, Jackson Ms 39216
Graduation Year: 1978
Hospital
Hospital: Rutherford Hospital, Rutherfordton, Nc; St Lukes Hospital, Columbus, Nc
Group Practice: Foothills Urology

Data Provided by:
Stephen Charles Rochman, MD
(910) 485-8801
313 Farley Pl
Fayetteville, NC
Specialties
Urology
Gender
Male
Education
Medical School: Meharry Med Coll Sch Of Med, Nashville Tn 37208
Graduation Year: 1970

Data Provided by:
Robert Albert Appel, MD
(910) 485-8151
1786 Metromedical Dr
Fayetteville, NC
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Va Sch Of Med, Charlottesville Va 22908
Graduation Year: 1981

Data Provided by:
Garrett Franzoni, MD
(910) 485-8801
1537 Owen Park Ln
Fayetteville, NC
Specialties
Urology
Gender
Male
Education
Medical School: Georgetown Univ Sch Of Med, Washington Dc 20007
Graduation Year: 1989

Data Provided by:
William Rand Jordan, MD
(919) 484-3261
1 Lilly Dr
Fayetteville, NC
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Nc At Chapel Hill Sch Of Med, Chapel Hill Nc 27599
Graduation Year: 1970

Data Provided by:
Joseph Mc Kendrie Jenkins, MD
(910) 484-5539
2848 Skye Dr
Fayetteville, NC
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Nc At Chapel Hill Sch Of Med, Chapel Hill Nc 27599
Graduation Year: 1974

Data Provided by:
Henry Edward Parfitt Jr, MD
(910) 485-8151
1786 Metromedical Dr
Fayetteville, NC
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Nc At Chapel Hill Sch Of Med, Chapel Hill Nc 27599
Graduation Year: 1975

Data Provided by:
DeOgracia Quinones
(910) 485-8801
1537 Owen Park Ln
Fayetteville, NC
Specialty
Urology

Data Provided by:
Robert Lee Hines, MD
(910) 483-4938
3637 Cape Center Dr
Fayetteville, NC
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Nc At Chapel Hill Sch Of Med, Chapel Hill Nc 27599
Graduation Year: 1978

Data Provided by:
Data Provided by:

Chemo Regimen for Ovarian Cancer

Provided By:

SUNDAY, Sept. 20 (HealthDay News) -- Dose-dense chemotherapy improves survival in women with advanced ovarian cancer, Japanese researchers say.

Currently, paclitaxel and carboplatin given every three weeks is considered standard first-line chemotherapy for advanced epithelial ovarian cancer. However, dose-dense weekly treatment with paclitaxel is seen as a way to increase progression-free and overall survival in these patients, according to the new study findings.

This phase 3 study of 637 women compared the two approaches. The participants had advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

The 320 patients in the conventional regimen group received six cycles of paclitaxel (180 milligrams per meter squared; three-hour intravenous infusion). The 317 patients in the dose-dense group received paclitaxel (80 milligrams per meter squared; one-hour intravenous infusion) on days one, eight and 15. Both groups received carboplatin on day one of a 21-day cycle.

The patients in the dose-dense group had longer median progression-free survival than those in the standard treatment group (28 months versus 17 months), and longer overall survival at three years (72 percent versus 65 percent). This means that women in the dose-dense group had a 29 percent lower risk of cancer progression and a 25 percent lower risk of death, the authors explained.

Toxicity forced 113 patients in the dose-dense group and 69 patients in the conventional therapy group to stop treatment, the researchers noted. Severe anemia occurred in 214 patients (69 percent) in the dose-dense group and in 137 (44 percent) of the standard therapy group.

The survival benefits seen in the dose-dense group are rare in patients with advanced ovarian cancer, and this regimen offers a new treatment option for women with advanced epithelial ovarian cancer, concluded Dr. Noriyuki Katsumata, of the National Cancer Center Hospital in Tokyo, and colleagues.

The study, published in an upcoming print issue of The Lancet, was released online Sunday to coincide with the European Cancer Organization meeting held Sept. 20 to 24 in Berlin.

"The use of such dose-dense therapy should be decided on an individual basis together with other options for women with advanced-stage ovarian cancer," Dr. Michael A. Bookman, of the Arizona Cancer Center in Tucson, wrote in an accompanying commentary in The Lancet.

More information

The U.S. National Cancer Institute has more about ovarian cancer.

SOURCE: The Lancet, news release, Sept. 19, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com